PLEKHG5 is a novel prognostic biomarker in glioma patients
- 110 Downloads
PLEKHG5, a Rho-specific guanine-nucleotide exchange factor, is involved in tumor cell migration, invasion and angiogenic potential. In this study, the expression pattern, prognostic value and function of PLEKHG5 in gliomas were investigated.
Immunohistochemistry was used to determine the expression pattern of PLEKHG5 in 61 glioma patients after curative resection. Statistical analysis was performed to evaluate the diagnostic and prognostic significance of PLEKHG5. Gene ontology (GO) analysis, Kyoto encyclopedia of genes and genomes (KEGG) pathway analysis and Gene set enrichment analysis (GSEA) were used to predict potential functions of PLEKHG5. Migration assay and western blot analysis determined PLEKHG5 function in glioma migration and invasion.
Increased PLEKHG5 expression levels were associated with higher glioma grades (P < 0.05). In addition, glioblastomas multiforme have higher ratio and stronger intensity of PLEKHG5 expression compared with low-grade gliomas. High expression level of PLEKHG5 indicated poorer prognosis and shorter survival time in all glioma patients (P < 0.001). GO analysis, KEGG pathway analysis and GSEA analysis suggested that PLEKHG5 was involved in glioma migration, invasion and epithelial–mesenchymal transition. Migration assay and western blot analysis revealed PLEKHG5 promoted glioma migration and invasion.
Our results demonstrated PLEKHG5 could be used as a novel prognostic biomarker and anti-tumor target for glioma patients.
KeywordsGlioma PLEKHG5 Novel prognostic biomarker Tumor migration and invasion
This work was supported by Grants from the National Natural Science Foundation of China (nos. 30872645, 81101594, 81372719, 81172403, 81402077, 81571284, 91542115, 81702468, 81874083, 81802966), National Natural Science Foundation of Shandong Province of China (no. 2017CXGC1203, 2017G006012, 2013GGE27006) and Taishan Scholars of Shandong Province of China (no. ts201511093).
Compliance with ethical standards
Conflict of interest
The authors declare no conflict of interest.
Research involving human participants and/or animal
Ethical approval for using human samples in this study was obtained from the local ethics committee.
Patients gave consent for the use of their tumor tissues for future investigations, which had been performed for many years at time of the initial diagnosis.
- 1.Ostrom QT, Bauchet L, Davis FG et al (2014) The epidemiology of glioma in adults: a "state of the science" review. Neurooncology 16(7):896–913Google Scholar
- 5.Nutt CL, Mani DR, Betensky RA et al (2003) Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Can Res 63(7):1602–1607Google Scholar